1. Effect of Spironolactone on 30-Day Death and Heart Failure Rehospitalization (from the COACH Study).
- Author
-
Maisel, Alan, Yang Xue, van Veldhuisen, Dirk J., Voors, Adriaan A., Jaarsma, Tiny, Pang, Peter S., Butler, Javed, Pitt, Bertram, Clopton, Paul, and de Boer, Rudolf A.
- Subjects
- *
SPIRONOLACTONE , *HEART failure treatment , *BIOMARKERS , *HEALTH outcome assessment , *NATRIURETIC peptides , *GALECTINS , *THERAPEUTICS ,CARDIOVASCULAR disease related mortality - Abstract
The aim of our study is to investigate the effect of spironolactone on 30-day outcomes in patients with acute heart failure (AHF) and the association between treatment and outcomes stratified by biomarkers. We conducted a secondary analysis of the biomarker substudy of the multicenter COACH (Co-ordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure) trial involving 534 AHF patients for 30-day mortality and HF rehospitalizations. Spironolactone therapy was initiated and terminated at the discretion of the treating physician; 30-day outcomes were compared between patients who were treated with spironolactone and those who were not. Outcomes with spironolactone therapy were explored based on N-terminal proeB-type natriuretic peptide, ST2, galectin-3, and creatinine levels. Spironolactone was prescribed to 297 (55.6%) patients at discharge (158 new and 139 continued). There were 19 deaths and 30 HF rehospitalizations among 46 patients by 30 days. Patients discharged on spironolactone had significantly less 30-day event (hazard ratio 0.538, p[0.039) after adjustment for multiple risk factors. Initiation of spironolactone in patients who were not on spironolactone before admission was associated with a significant reduction in event rate (hazard ratio 0.362, p[0.027). The survival benefit of spironolactone was more prominent in patient groups with elevations of creatinine, N-terminal proeB-type natriuretic peptide, ST2, or galectin-3. In conclusion, AHF patients who received spironolactone during hospitalization had significantly fewer 30-day mortality and HF rehospitalizations, especially in high-risk patients. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF